Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Show other versions (1)

Bibliographic Details
Main Authors:	Mohammed A. Osman, Mohammad S. Elkady, Khalid E. Nasr
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-04-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/weekly-paclitaxel-versus-three-weekly-paclitaxel-in-recurrent-platinum-article-a5556

Similar Items

Weekly Paclitaxel versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
by: Mohammed A. Osman, et al.
Published: (2016-01-01)

Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2020-01-01)

Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
by: Hanan Shawky, et al.
Published: (2014-09-01)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
by: S B Dessai, et al.
Published: (2016-01-01)

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer
by: Blagden Sarah, et al.
Published: (2011-07-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
by: E. A. Wist, et al.
Published: (2012-01-01)

Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
by: Bacinschi XE, et al.
Published: (2020-02-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group
by: Kenro Hirata, et al.
Published: (2020-06-01)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
by: Kim Hyae, et al.
Published: (2011-09-01)

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study
by: Akash Mathur, et al.
Published: (2018-01-01)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004-09-01)

Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
by: Wang HY, et al.
Published: (2016-09-01)

Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma
by: Gaetano Apice, et al.
Published: (2016-01-01)

Comparative Effectiveness of Platinum plus Paclitaxel versus Platinum plus Cyclophosphamide in Patients with Early-staged Ovarian Cancer
by: Chien-An Chen, et al.
Published: (2014)

Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin
by: Hala Mohamed El-Shenshawy, et al.
Published: (2012-10-01)

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study
by: G. Buccheri, et al.
Published: (2016-02-01)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
by: Moore Carla L, et al.
Published: (2010-03-01)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
by: Vanita Noronha, et al.
Published: (2016-01-01)

Quasi-Complete Response of Classic Kaposi’s Sarcoma Treated with Weekly Paclitaxel
by: Zineb Benbrahim, et al.
Published: (2013-01-01)

Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
by: Yong Han, et al.
Published: (2012-01-01)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020-11-01)

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma
by: Nam Bui, et al.
Published: (2018-04-01)

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
by: Charafeddine Maya, et al.
Published: (2010-09-01)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
by: Paglia Amelia, et al.
Published: (2006-07-01)

Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer
by: Dong Choon Park, et al.
Published: (2008-09-01)

Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer
by: HOU Wenjie, et al.
Published: (2018-06-01)

Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer
by: Gang Cai, et al.
Published: (2019-07-01)

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
by: Tichá Alena, et al.
Published: (2007-08-01)

Serial Urinary Neopterin Measurements Reflect the Disease Course in Patients with Epithelial Ovarian Carcinoma Treated with Paclitaxel/Platinum Chemotherapy
by: Melichar Bohuslav, et al.
Published: (2007-02-01)

Phase 1 study of one-week chemotherapy with paclitaxel and carboplatin in patients with metastatic bladder cancer
by: M. Johansen, et al.
Published: (2020-02-01)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
by: Weng CS, et al.
Published: (2019-11-01)

Prospective Randomized Study Comparing Concomitant Chemoradiotherapy Using Three Weekly Cisplatin and Biweekly 5-Fluorouracil versus Weekly Paclitaxel in Locally Advanced Carcinoma Cervix
by: Sapna Marcus, et al.
Published: (2018-07-01)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020-09-01)

Inhibition of Notch signaling in combination with paclitaxel reduces platinum-resistant ovarian tumor growth
by: Jolijn W Groeneweg, et al.
Published: (2014-07-01)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
by: Sun S, et al.
Published: (2014-03-01)

Weekly Paclitaxel and Cisplatin in the Treatment of Elderly Advanced Non-small Cell Lung Cancer
by: Ying LIANG, et al.
Published: (2009-10-01)

Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study
by: Deepa M. Joseph, et al.
Published: (2021-09-01)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
by: Elizabeth K. Lee, et al.
Published: (2019-08-01)